Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04119024
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:12.760452+00:00
Published At
2026-03-17T00:00:00+00:00
Record Updated At
2026-03-17
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Uveal Melanoma", "Acral Melanoma", "Neuroendocrine Tumors", "Paraganglioma", "Pheochromocytoma", "Adrenocortical Carcinoma", "Pancreatic Neuroendocrine Tumor", "Thyroid Cancer", "Breast Cancer", "Lung Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-17"
protocolSection.identificationModule.nctId
"NCT04119024"
protocolSection.identificationModule.officialTitle
"Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Metastatic Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Metastatic Melanoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Uveal Melanoma (protocolSection.conditionsModule.conditions)
  • Acral Melanoma (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Tumors (protocolSection.conditionsModule.conditions)
  • Paraganglioma (protocolSection.conditionsModule.conditions)
  • Pheochromocytoma (protocolSection.conditionsModule.conditions)
  • Adrenocortical Carcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Neuroendocrine Tumor (protocolSection.conditionsModule.conditions)
  • Thyroid Cancer (protocolSection.conditionsModule.conditions)
  • Breast Cancer (protocolSection.conditionsModule.conditions)
  • Lung Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.